Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.
about
Morgellons disease: a filamentous borrelial dermatitisEstablished Population of Blacklegged Ticks with High Infection Prevalence for the Lyme Disease Bacterium, Borrelia burgdorferi Sensu Lato, on Corkscrew Island, Kenora District, OntarioLyme disease: the promise of Big Data, companion diagnostics and precision medicinePrevalence of the Lyme Disease Spirochete, Borrelia burgdorferi, in Blacklegged Ticks, Ixodes scapularis at Hamilton-Wentworth, OntarioSuicide and Lyme and associated diseases.Lyme neuroborreliosis-epidemiology, diagnosis and management.Update on persistent symptoms associated with Lyme disease.Chronic Lyme disease: misconceptions and challenges for patient managementProgress in the molecular diagnosis of Lyme disease.Application of Nanotrap technology for high sensitivity measurement of urinary outer surface protein A carboxyl-terminus domain in early stage Lyme borreliosis.In vitro evaluation of antibacterial activity of phytochemicals and micronutrients against Borrelia burgdorferi and Borrelia garinii.Efficacy and safety of pharmacological agents in the treatment of erythema migrans in early Lyme borreliosis-systematic review protocol.Cooperation of Doxycycline with Phytochemicals and Micronutrients Against Active and Persistent Forms of Borrelia spControversies in Persistent (Chronic) Lyme Disease.Detection of Lyme Disease Bacterium, Borrelia burgdorferi sensu lato, in Blacklegged Ticks Collected in the Grand River Valley, Ontario, Canada.The Potential of Omics Technologies in Lyme Disease Biomarker Discovery and Early Detection.Antibiotics for the neurological complications of Lyme disease.Living in Limbo: Contested Narratives of Patients With Chronic Symptoms Following Lyme Disease.Empirical validation of the Horowitz Multiple Systemic Infectious Disease Syndrome Questionnaire for suspected Lyme disease.Tocilizumab Efficacy in a Patient with Positive Anti-CCP Chronic Lyme Arthritis.Cutaneous Lyme borreliosis: Guideline of the German Dermatology Society.In vitro susceptibility of Borrelia burgdorferi isolates to three antibiotics commonly used for treating equine Lyme disease.Lyme Disease guidelinesThe Lyme law.“Late You Come: Legislation on Lyme Treatment in an Era of Conflicting Guidelines”.The Financial Implications of a Well-Hidden and Ignored Chronic Lyme Disease Pandemic.Cost-effectiveness of longer-term versus shorter-term provision of antibiotics in patients with persistent symptoms attributed to Lyme disease.Aggressiveness, violence, homicidality, homicide, and Lyme disease.Persistent Borrelia Infection in Patients with Ongoing Symptoms of Lyme Disease.Motivations and Experiences of Canadians Seeking Treatment for Lyme Disease Outside of the Conventional Canadian Health-Care System.Relapsing fever in California: a pilot serological studyNeuropsychiatric Lyme Borreliosis: An Overview with a Focus on a Specialty Psychiatrist's Clinical Practice
P2860
Q28072515-47ACD7FF-7ECE-4A49-852D-9922B33136D3Q28820915-80E963B1-B693-4A13-B8DE-1CDC9834F14FQ28830150-C53829D3-A5F1-4A83-9FE9-F5672D63B1F6Q28833508-C0059418-723E-46B0-86BF-163205BFE281Q33825891-D77B0172-325E-42E5-AEDA-1CE0A559BF6AQ34487119-B5EEFCAD-972F-4A2A-8175-7F8819373E59Q35562720-103704F7-96BB-4C13-BCC9-4D1CF5C4D933Q35633278-E5BEC50A-F51C-4220-802D-89DC2180B389Q36205210-5C26A8DD-0530-4BA0-8E84-9D6528390B9CQ36253022-3A2FA8C9-842C-4F92-A6E5-30152C75DBD2Q36536889-71A79581-7C39-4766-ADDD-91482BD7B6C5Q36865740-DF26FCD5-F15A-4143-82B2-8A93F8F0C558Q37201989-33CB0650-3CF9-42CE-842D-B9CE23D9B64DQ37403994-DF2614FD-2BD4-4491-9F87-85E00832B9A5Q37675844-18A1DED0-AEC3-459E-9884-23C46A0FD668Q37679914-D973488E-C14F-4E9B-82D0-99185F75097FQ39032987-571B85C2-23C0-47B2-A772-3C9E4536E487Q40885128-ABEA1590-C414-47D0-9D20-5F56161CCA6CQ41503473-AF47FC6A-30CD-448E-AB72-0ECCE6086A5CQ41540311-F817690C-C187-4139-8A69-A815B4760205Q41594433-C6B9814E-03B1-4925-80AD-1C37DD8FE0CAQ42183764-C297DFD5-616F-41F6-9C1B-D314C1933300Q42427267-FA0E0043-3FC1-40B8-A2EC-54CF70A47309Q42616673-D5576CFA-39CE-457D-8981-FB4ADAB69F5CQ47114019-4079D271-0E1C-4E38-8120-F74F455EB6C0Q50041916-478A8170-4695-4B34-922F-37DE27EBDD17Q52613295-F3C3D041-C1A2-4D42-B2F9-8E104AE02383Q53426045-47EC4974-70F0-4D07-A534-CC1819AB5BB2Q54091973-74527ADA-D176-4DEC-A183-C063AB09D066Q55423887-3E0487E1-1D2F-4CD9-A6C3-AB22FF578A3BQ57071198-71DE8C9D-7723-4920-927E-7F809804EEEAQ58702457-3551C090-3F06-411F-A782-28CA09BFE361
P2860
Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Evidence assessments and guide ...... rashes and persistent disease.
@ast
Evidence assessments and guide ...... rashes and persistent disease.
@en
Evidence assessments and guide ...... rashes and persistent disease.
@nl
type
label
Evidence assessments and guide ...... rashes and persistent disease.
@ast
Evidence assessments and guide ...... rashes and persistent disease.
@en
Evidence assessments and guide ...... rashes and persistent disease.
@nl
prefLabel
Evidence assessments and guide ...... rashes and persistent disease.
@ast
Evidence assessments and guide ...... rashes and persistent disease.
@en
Evidence assessments and guide ...... rashes and persistent disease.
@nl
P2093
P2860
P1476
Evidence assessments and guide ...... rashes and persistent disease.
@en
P2093
Daniel J Cameron
Elizabeth L Maloney
Lorraine B Johnson
P2860
P304
P356
10.1586/14787210.2014.940900
P5008
P577
2014-07-30T00:00:00Z
2014-09-01T00:00:00Z